Member Info for crumbs

I think the time it takes to get suitable patients into the trial is a given the real problem from my perspective is we have only one recruitment centre Nottingham... If we do not get more it is going to be difficult to recruit enough to meet 25... like I said the other day we could be looking at a trial where data distance from first dosed and last dosed could be 5 years or something!... trial is supposed to be finished by 2023.... I know this has something to do with getting the Keytruda paid for by the clinics... must be difficult however I think existing data should be compelling enough to convince the worth and surely we are trying to get the same UK centres as used in the original mono trial..

Sally defo says yes about the first patient dosed will be RNS'd

I take it Cliff hasn't gotten back in reply to your email yet?

'(Reuters) - AstraZeneca Plc said on Monday a combination of its cancer drug, Imfinzi, along with chemotherapy helped curb progression of lung cancer in a late-stage study, sending its shares up 2%.

The combination, when added to the drugmaker’s tremelimumab therapy, also met the secondary goal of improving progression-free survival, the British drugmaker said.

The combinations were being tested in previously untreated patients with stage four, non-small cell lung cancer.'

https://uk.reuters.com/article/us-astrazeneca-cancer-drug/astrazeneca-cancer-drug-combo-meets-late-stage-trial-goal-idUKKBN1X71O8

Yes, and throw in fact they have their own CI keytruda alternatives as well as keytruda... If oncosec pulled it off... though they did manage to get combo data before scancell then really scancell must be attractive to someone there!...

telling ya!

The surge comes after Hong Kong relaxed its rules last year to encourage biotech firms with no record of profit or revenue to list. The other eight such companies that debuted since that change gained an average 18% from their offer prices, Bloomberg-compiled data show.

“Investors have a particular interest in the health-care sector, especially biotech firms given they usually have a good growth outlook,” said Albert Yu, an analyst at Zhongtai Financial International Ltd. “The company should be able to generate strong profits once it is able to commercialize its products.”

China is investing billions in its hospitals and has revamped its drug approval system to get novel medications quickly to its population. The country has the world’s biggest patient pool for diabetes, and almost 4 million people are diagnosed with cancer each year.'

If CH emails back saying he is in China we might be getting somewhere lol

Elsewhere for bio stocks :

'Ascentage Pharma Group International went from Hong Kong’s hottest initial public offering this year to a huge debut as investors continue to embrace unproven Chinese health-care companies.

The developer of cancer and hepatitis B therapies soared as much as 57% on Monday before paring the gain to 9.9% at the close. The firm’s retail portion of its offering was more than 750 times oversubscribed last week, the highest ratio among Hong Kong listings this year, according to data compiled by Bloomberg.'
https://www.bloomberg.com/news/articles/2019-10-28/hong-kong-s-biotech-ipo-craze-continues-as-ascentage-soars-57

It would only be a crumbs sized buy though lol... yours sounds more substantial... trouble is how low are we going.....

Yeah Chester I'm going to have to look at this now as a buying more shares opportunity 'grudingly' as really I just want it to fly I'm ok with my holding... but will take more and get the as violin would say depressing average down a bit... As for pharma moving on and SCIB1 hmm I don't think so there that is not a lost caused but we need to be in it to win it! CI need help late-stage melanoma is still a killer all be it one that can now be treated with more options than before ..... we need that data but if no patient wants to enrol and no more recruiting centres open up we are a bit stuck

Well, all is not lost yet lol... but I get your feeling ... what should be a success is dragging us down and has been for years now seemingly with no end luckily this company is not a SCIB1 only company be goodness do we need a newslfow boost

Don't think it is as simple as just suspending.... We have a very expensively manufactured vaccine ... not something to just pour down the drain plus there is the new 'commercial' Ichor device no doubt already shipped over.... seems we are committed to it, at the moment 1 dosed patient is looking like a miracle never mind 25

The trial has started in Nottingham they are recruiting or trying to... but no patient dosed yet and no more clinics

It's a battle! A losing one..... but the war is not over

One shakes the test tubes and the other moves them over to Roche :)

Yeah, it's good to talk:) anyways I think she is an addition with potential... interestingly Discuva, where she was at, had a nice Roche deal in place and then got bought out by Summit .... Anyways I hope she is more on the phone to the US talking to a big player about scancell plans than mediating between Cliff and Lindy lol

'Ursula Ney, Portfolio
Non-Executive Director
Ursula’s work as a Non-Executive Director
centres on changing how people within
organisations collaborate internally and
externally with contractors and pharma
partners. Biotech specialisms continually
evolve, and so does the need to challenge
the rationale for corporate divisions of
activity. She is a Non-Executive Director
of Discuva, a Cambridge UK based start
up and the AIM listed Proteome Sciences
plc. Ursula has also led integration of
merging companies where cross company
collaboration has been a key priority to
drive a common culture.
Over the last 30 years she has been an
Executive Director at Celltech plc and
Antisoma plc and CEO of Genkyotex'

http://www.mws-consulting.co.uk/wordpress/wp-content/uploads/2017/11/50-Movers-and-Shakers-in-BioBusiness-2017-WEB-final-311017.pdf

notice Lindy made that list .....

The Albatros... It all started so well the esteemed number one melanoma clinician Keith Flaherty approaching scancell at a US conference wanting to run a combo trial in the US in some of the best clinics involving other top US clinicians...too good to turn down! We were excited too... even though we all knew it would come with a pricetag but none of us could have foreseen what has seen unfolded ... time delays no big money backer coming in... then the FDA!!! brick wall... now a UK focused trial that seems is struggling to get out of Nottingham and not looking like its managing to attract participants at any speed.... how much are the BOD to blame.... well blame might not be the right word but at the end of the day they are all paid rather well and are all 'experienced' ....badly handled with some misleading thrown in with regards FDA and reluctant UK arm .....We are stuck with it ... But thing is 14/16 patients with late-stage melanoma could well be alive and hopefully well now because of being treated with SCIB1 .....you'd think that would get a just reward...so far it hasn't and we are stuck with the consequences that have definitely affected sp and sentiment badly here.... still this not a one-trick pony so loads of positive newsflow is always possible....and again SCIB1 is not itself a failure it is probably one of the very few successful cancer vaccine trials with even lung tumour shrinkage shown which is no doubts reason Keith Flaherty wanted and as far as we know still wants to be involved in getting it further studied in human trial.

'The first ImmunoBodyTM, SCIB1, has completed a phase I/II clinical trial in which 14/16 patients with melanoma have been disease free for five years.'

how this has not translated into sp via someone coming in is still baffling... very possible those patients are still disease-free and indeed 'cured; as now most will be heading into 6-7 years ..... you consider the billions spent on 'dead ends'
baffled....
And failure to get this product into a further viable combo trial that could cement its viability as a life-saving treatment... baffling

Just a little post... We had a few posts of questioning the judgements Martin Diggle and our new appointee Ursula... fair enough they have histories that we can view and it is not all success..indeed Vulpes investment in scancell at 5p could soon be challenged by an sp under 5p! .... however that is not what I want to focus on what I wanted to say is what is different about scancell compared to many others and it is indeed the science..,.. scancell is a science-driven company ... moditope was discovered many years ago now but the understanding and expanding of knowledge around it and indeed turning it into a clinically viable product has never stopped... all scancells techs are scancells techs the ip belongs under Lindys umbrella ....IIt is why I am here and remain here and will remain here despite the timeline issues and continued erosion of mcap.... from the forthcoming neoantigen conference in Boston USA....

'Lindy is Professor of Cancer Immunotherapy at the University of Nottingham and CSO of Scancell Ltd. She has developed two vaccine platforms ImmunoBodyTM and ModitopeTM which induce potent killer CD8 T cells and and cytotoxic CD4 T cells to post-translational modifications respectively. The first ImmunoBodyTM, SCIB1, has completed a phase I/II clinical trial in which 14/16 patients with melanoma have been disease free for five years. The first product from the ModitopeTM platform will enter the clinic next year. Lindy has over 150 peer reviewed publications and is also the inventor on 66 patents, 55 of which have been awarded. She was award of the Waldenstrom prize for cancer Immunotherapy in 2018.'

This is pioneering territory... how to back the eventual winners?

Well probably not for the trial you're right, though I seem to remember that their thinking on it being a restricting factor to responding changed later on and you don't see it mentioned anymore unlike in earlier presentations... hopefully we will get more info on the final makeup of the trial it as we approach the possible beginning date....Also hopefully it is run with a big backer behind it too :)))